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ABSTRACT
Objectives To describe the characteristics and outcomes 
of hospitalised patients with COVID-19 from UK in the 
highest decile of health and gross regional products per 
capita.
Design Prospective cohort study.
Setting Recruited all adult inpatients with laboratory- 
confirmed COVID-19 symptoms admitted to a single 
Surrey centre between March and April 2020. Extensive 
demographic details were documented.
Outcome measure COVID-19 status of alive/dead and 
intensive care unit (ICU) status of yes/no.
Participants Patients with COVID-19 from Surrey centre 
UK (n=429).
Results 429 adult inpatients (mean age 70±18 years; 
men 56.4%) were included in this study, of whom, 19.1% 
required admission to ICU and 31.9% died. Adverse 
outcomes were associated with age (OR with each decade 
of years: 1.78, 95% CI 1.53 to 2.11, p<0.001 for mortality); 
male gender (OR=1.08, 95% CI 0.72 to 1.63, p=0.72, 
present in 70.7%, of admissions to ICU versus 53% of 
other cases, p=0.004); cardiac disease (OR=3.43, 95% CI 
2.10 to 5.63, p<0.001), diabetes mellitus (OR=2.37, 
95% CI 1.09 to 5.17, p=0.028) and dementia (OR=5.06, 
95% CI 2.79 to 9.44, p<0.001). There was no significant 
impact of ethnicity or body mass index on disease 
outcome.
Conclusions Despite reports of worse outcomes in 
deprived regions, we show similar complication and 
mortality rates due to COVID-19 in an affluent and high life 
expectancy region.
INTRODUCTION
An emerging theme of SARS- CoV-2 infec-
tion is wide variability in incidence, presen-
tation and prognosis, between countries1 
and between regions within countries.2 3 
Understanding which factors underpin this 
heterogeneity is critical to understanding the 
biology of COVID-19 and guiding therapeutic 
and preventative strategies.
One of the most surprising findings for 
an infectious disease is that nations with 
high gross domestic product per capita show 
higher rates of COVID-19 infection, and 
mortality, than nations with lower economic 
performance.1 Possible explanations for this 
paradox include richer nations tending to 
have larger cities, whose inhabitants travel 
more widely, are older, and have higher 
rates of cardiovascular disease, diabetes and 
obesity—all recognised adverse prognostic 
features.4 5 Recent data from the UK and 
USA suggest that contrary to this interna-
tional trend, regional deprivation is strongly 
associated with higher COVID-19- associated 
mortality,6–8 which may reflect differences 
in ethnic profile, background health, social9 
and behavioural factors of transmission10 and 
public health infrastucture.7
When comparing regions, differences in 
personal factors like demographic or health 
status can be complicated by local organisa-
tional differences like hospital capacity or 
primary care referral patterns. To help tease 
apart these factors, we present a large cohort 
of COVID-19 infections admitted to a single 
UK centre covering one geographical region, 
Surrey county,11–13 which represents one of 
the most affluent and homogeneous popula-
tions in the UK. The gross regional domestic 
product per capita of Surrey and healthy 
life expectancy are both within the top UK 
deciles while levels of adult obesity, smoking 
and physical inactivity are significantly lower 
than the national average,14 with 90.4% being 
white,14 higher than the national average.11
Strengths and limitations of this study
 ► Sample size with established outcome is greater 
than many other UK COVID-19 cohorts.
 ► Surrey represents the greatest proportion of high 
socioeconomic status residents compared with any-
where else in the UK.
 ► The number of patients from any one ethnic group 
was limited.
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From this relatively healthy and socially advantaged 
cohort, we questioned whether demographic, clinical 
outcome and prognostic features of COVID-19 infection 
differ from those described in more diverse and deprived 
international regions.
METHODS
This study includes adult inpatients (≥18 years old) from 
St Peters Hospital, Surrey. We included all prospective 
patients with laboratory- confirmed COVID-19 infection 
who were admitted between March and April 2020. The 
recruitment dates incorporate the initial surge of cases 
seen in the UK, the estimated peak and the subsequent 
decline. Case confirmation was defined by a positive result 
on a COVID-19 reverse- transcription–polymerase chain 
reaction assay of a specimen collected on a nasopharyn-
geal swab. Demographic data were manually extracted 
from electronic health records.
Extensive patient data were collected and analysed from 
admission through to completion of the episode of care 
and included demographics, exposure history, typical 
symptomatology, comorbidities, treatment, complica-
tions and outcome. Many participants were coenrolled in 
other interventional studies and clinical trials.
Data analysis
Descriptive statistics were summarised using mean with 
SD or median with IQR for continuous variables and 
proportion for categorical variables. The χ2 was used for 
single factor analysis of categorical variables. Independent 
t- test or Mann- Whitney U test was used for single factor 
analysis of continuous variables. Univariate and multivar-
iate logistic regressions were used to estimate the associ-
ations of risk factors with COVID-19 status. The subset of 
risk factor providing the best fit to the data, among all 
the possible models, was selected using stepwise model 
selection by number of criteria: Akaike information crite-
rion (AIC), Bayesian information criterion, Mallow’s Cp, 
residual mean square, a leave- one- out cross- validation, 
receiver operating characteristic curve (ROC curve), 
Youden index and conditional analysis. To check how 
sample size affects the results of variable selection proce-
dure, we randomly selected a proportion of the original 
dataset to apply the stepwise AIC procedure used in the 
main analysis and repeated the procedure 1000 times. The 
significance threshold is a trade- off between avoidance 
of false- positive associations while considering the likely 
higher prior of association because of the nature of the 
array. However, there are high correlations between pairs 
variables, therefore, the Bonferroni correction would be 
too conservative for the analysis. In addition, type- I errors 
are random, and patterns in results that confirm previous 
reports should be given more weight than isolated results 
with a single low p value. Correction for multiple compar-
isons largely increases the likelihood of type- II errors and 
important differences considered non- significant. To 
consider this, for individual tests of association, rather 
than applying a correction for multiple testing at global 
significance level, defined statistical significance as 0.01. 
Analyses and graphics were performed and produced 
using R V.4.0.0.
Patient and public involvement
This study was undertaken during the height of the UK 
coronavirus pandemic. It was not possible for patients or 
their advisors to be involved in the design of this study.
RESULTS
A total of 429 patients were included, none of whom were 
lost to follow- up. Patients were typically elderly (mean 
age: 70±18 years), men (56.4%) and white (72.5%). 
Comorbidity and symptom frequencies are shown in 
table 1. Only small fractions of patients had recently trav-
elled to a country with known transmission (1.2%) or had 
recent contact with a person known to have confirmed 
COVID-19 (5.4%).
Course and outcome
The proportion of patients requiring admission to inten-
sive care unit (ICU) was 82/429 (19.1%), 14.2% of which 
required non- invasive ventilation and 7% required inva-
sive ventilation. Patients who were admitted were signifi-
cantly younger (mean age of ICU admission 65±17 years vs 
71±18 years (p=0.002) and overwhelmingly men (70.7%, 
vs 53% of non- ICU patients, δ=17.7%, 95% CI 7% to 29%; 
p=0.004) (table 1).
Superadded bacterial pneumonia was diagnosed in 
28 patients (6.5%). The most common complications of 
infection included viral pneumonia (23.3%), acute respi-
ratory syndrome (13.1%), acute kidney injury (7.9%), all 
of which were associated with death (p values all <0.001). 
Nine (2.1%) patients required renal replacement therapy 
or dialysis.
Prognostic factors
The strongest risk factor for mortality in COVID-19 was 
age (OR=1.78 for each decade of life, 95% CI 1.53 to 2.11, 
p<0.001) (figure 1). Symptoms associated with mortality 
were dehydration, altered consciousness or confusion 
and increased respiratory rate (p values all <0.001). 
Conversely, myalgia (p=0.006), sore throat (p=0.011), 
fever (p=0.021) and cough (p=0.048) at presentation 
were associated with reduced mortality (table 1). Inter-
esting, absence of fever and cough was associated with 
increased risk of death (p=0.007). On arrival to hospital, 
those who died had a significant difference in respiratory 
rate (survivor mean respiratory rate 22±8 vs 26±9 in non- 
survivors; p=0.001).
The mortality OR for continuous (figure 2) and binary 
(figure 3) variables are shown. Gender, body mass index 
(BMI) and smoking status were not significantly related 
to worse outcomes (table 1). Patients from non- European 
descent were nearly three times more likely to be admitted 
to hospital, but their overall outcome has no different 
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compared with Caucasian patients, although representa-
tion by different ethnicity groups was low in this region.
The predictive probability of death from COVID-19 
was analysed using the ROC curve (area under the 
curve=0.86, p<0.0001). We modelled six factors (age, C 
reactive protein (CRP), respiratory rate, diastolic blood 
pressure (BP), presence of dementia, asthma), which 
together explain 86% variance of mortality (table 2).
DISCUSSION
We describe a large cohort of confirmed patients with 
COVID-19 treated in a single hospital from one of 
the most affluent, socially homogeneous and healthy 
regions of the UK.11–13 Despite this regional advantage, 
the mortality (32%) and admission to ICU (19%) rates 
in hospitalised COVID-19 cases are similar to provi-
sional reports elsewhere in the country.15–17 Our finding 
that adverse outcomes for hospitalised patients from a 
wealthy, healthy region occurred at a similar frequency 
as recorded elsewhere in the UK lies in contrast to 
population- level data showing that mortality worsens 
with regional social deprivation and underlying health 
status.6–8 Among UK regions, age- standardised mortality 
rates due to COVID-19 were 118% higher in the highest 
deciles deprived regions, compared with the lowest 
deciles deprived area.8 Individual deprivation was 
also found to be an independent predictor of hospital 
mortality in an electronic health analysis of 17 million 
English healthcare records featuring 5683 COVID-19 
deaths.
One possible explanation for similar rates of adverse 
outcomes as cohorts elsewhere in UK is that hospital-
ised patients had a high level of recognised risk factors, 
even if these features were less common as a whole rela-
tive to the national average. This is seen in the demo-
graphic structure of admitted cases, with the average age 
being 70 years old, and men accounting for 56% these 
profiles previously associated with adverse outcomes7 18 
and comparable in proportion to those recorded from a 
UK- wide survey of COVID-19- hospitalised cases (median 
age: 72 years; 60% men).19 Additionally, the proportion 
of non- whites, a further risk for mortality,16 accounted 
for a disproportionately greater fraction of admissions 
(27.5%), than in Surrey as a whole (10%); while the rate 
of relevant comorbidities (eg, cardiovascular disease) was 
as high in our cohort as in other UK cohorts, although the 
numbers represented by each ethnic group is relatively 
low.17 Thus, the high- risk profile of hospitalised Surrey 
cohort patients helps to explain why their rate of adverse 
outcomes is similar to those reported in more deprived 
areas. Our results also suggest that inter- regional differ-
ences in COVID-19 outcome (eg, higher death rate in 
deprived areas)8 are more likely to be due to differences 
in frequencies of personal risk factors, rather than due 
Figure 1 Probability of survival from COVID-19% and 95% CIs among age.
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to variations in local healthcare structure, capability or 
intensive care capacity.
Data from the Intensive Care National Audit and 
Research Centre showed that a third of patients with 
COVID-19 admitted to critical care units are from 
an ethnic minority background.20 21 Of 2249 patients 
admitted to 201 critical care units in England, 64.8% were 
white, 13.8% were Asian, 13.6% were black and 7.8% 
were from other or mixed ethnic groups. Importantly, 
these unadjusted descriptive data take no account of 
factors other than ethnicity that could influence the risk 
of critical care admission. Ethnic minority groups have 
also been disproportionately affected by COVID-19 in the 
USA, highlighting potential racial, economic and other 
inequalities.20 An analysis by the Washington Post reports 
that those counties with black majorities have three times 
the rate of COVID-19 cases and almost six times the rate 
of deaths, compared with counties where white residents 
are in the majority.20 However, unlike the UK, the US 
experience may be influenced by the lack of universal 
healthcare and caution is required when extrapolating 
across different health systems. The higher observed 
incidence and severity in minority groups may be asso-
ciated with socioeconomic, cultural or lifestyle factors, 
genetic predisposition or pathophysiological differences 
in susceptibility or response to infection. Possible suscep-
tibilities include an increased risk of admission for acute 
respiratory tract infections,22 an increased prevalence 
of Vitamin D deficiency,23 vaccination policies in their 
country of birth and immune effects,20 increased inflam-
matory burden and higher prevalence of cardiovascular 
risk factors such as insulin resistance and obesity than 
white populations.24 Some of these are also risk factors 
for increased disease severity in COVID-19.20 25
In other respects, the characteristics and prognostic 
factors of our COVID-19 cohort were broadly similar to 
those described in cohorts from more diverse regions, 
with lower economic and health status.17 A third of admis-
sions were apyrexial; one- third had no cough and 15% 
had neither a cough or fever, indicating that a sizeable 
fraction of hospitalised cases do not meet current NHS 
England clinical criteria for suspected COVID-19 infec-
tion.26 Indeed, the absence of a cough and fever was asso-
ciated with a poorer outcome. Fever is the most common 
symptom among mild to moderate cases.27–37 However, 
the frequency varied among the studies. In the largest 
cohort study in Europe, fever was presented in 45.4% of 
the cases,33 while in the two largest studies in China, it 
was present at more than 80%35 36. Cough was the second 
most common symptom observed in all studies.27–37 The 
frequency with which it was observed varied among 
studies, and it was up to 63.2% in the largest European 
study33 and between 48.7%36 and 65.5%35 in the two 
largest Chinese studies. Cough was observed in 65.7 (95% 
CI 57.8 to 73.5) of patients with non- severe disease in the 
systematic review of studies in the general population38 
Figure 2 Forest plot showing the OR of death as outcome using logistic regression analysis for risk factor as continuous 
variables.
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and 46% of the systematic review of paediatric studies.31 
The biological mechanism of absence of fever or cough 
is unclear. It is possible that failure to mount an immune 
response is the reason for the poor outcome in the 
absence of fever or cough.
The strongest factor predicting COVID-19- associated 
mortality in our cohort was age, risk increasing by 6% with 
every additional year of life or by 78% with every additional 
decade (figure 2). This is similar to a study from China (OR 
per year increase 1.10, p=0.0043)39 and an international 
analysis (60 years old or older patients have an OR=18.8 
(95% CI 7.20 to 41.6)40 as well as clinical characteristics 
from coronaviruses causing SARS and Middle East Respira-
tory Syndrome epidemics.39 Strong associations of mortality 
were also seen with dementia, asthma, diastolic BP inline 
with other published literature41 42 as well as respiratory rate 
and CRP levels.
Figure 3 Forest plot showing the OR of death as outcome using logistic regression analysis for risk factor as binary variables. 
BIPAP, Bi- level Positive Airway Pressure; CPAP, Constant Positive Airway Pressure; HDU, High Dependency Unit; ICU,intensive 
care unit; IMC, Intermediate Care unit.
Table 2 Multivariate logistic regression analysis of COVID-19 risk factors
Risk factor
Model 1
OR (95% CI) P value
Model 2
OR (95% CI) P value
Model 3
OR (95% CI) P value
Age (decade) 1.78 (1.53 to 2.11)<0.001 1.89 (1.46 to 2.52)<0.001 1.89 (1.46 to 2.52)<0.001
CRP (5 mg/L) 1.04 (1.02 to 1.07)<0.001 1.04 (1.02 to 1.07)<0.001
Respiratory rate (breaths per minute) 1.05 (1.01 to 1.10) 0.019 1.05 (1.01 to 1.10) 0.013
DBP (5 mmHg) 0.87 (0.79 to 0.97) 0.012 0.87 (0.77 to 0.97) 0.015
Dementia 4.61 (1.81 to 12.48) 0.002
Asthma 3.22 (1.16 to 8.92) 0.023
AIC 473.83 248.84 224.65
Sensitivity/specificity 0.84/0.51 0.86/0.67 0.70/0.86
AUC (95% CI) 0.72 (0.68 to 0.77) 0.83 (0.78 to 0.88) 0.86 (0.81 to 0.91)
AIC, Akaike information criterion; AUC, area under the curve; CRP, C reactive protein; ; DBP, diastolic blood pressure.
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The admission rate to intensive care in our COVID-19 
cohort (19%) was similar to reports from Italy (10%) 
and America (14%),41 43 but significantly lower than 
China (26%).39 Cough at presentation, lymphocytopenia 
and raised alanine aminotransferase (ALT) discrimi-
nated between those who could and those who could not 
avoid ICU admission, in line with other published data.35 
However, factors we found that predicted fatality in ICU 
were raised urea and raised creatinine, which have not yet 
been reported elsewhere. Of those admitted to ICU, 47.6% 
died, compared with 28.4% who received ward- based care. 
This is line with national data (45%)19 and compares to a 
broad international range early Chinese data 16%–78%, 
Italy 26%, USA 50%.19 44–46
Our modelling data predict six factors that account 
for 86% of the mortality variance with age being the 
best predictor, accounting for 72% of the model by itself 
(table 2). One prognostic association in our cohort that 
differs from other reports46–48 is that BMI was not a statis-
tically significant factor predicting mortality, despite the 
average BMI of admitted patients being raised (28 kg/m2). 
In fact, we found that raised BMI shows a trend towards 
protection in women. An obesity survival paradox with 
pneumonia has previously been described49 and may arise 
because of more aggressive treatment provided to these 
patients or increased metabolic reserve enabling prolonged 
treatment in intensive care. The fact that ‘protective obesity’ 
was found only in women suggests there may also be some 
role of or difference in sex hormones and fat deposition 
patterns. Another reason for discrepancies between reports 
in the effect of BMI on survival may arise from the method 
by which BMI was measured. Using a different measure of 
obesity (‘recognised by clinical staff’) led to a significantly 
positive association with mortality, as observed elsewhere.19
There are several limitations to our study. First, as we are 
still early in our epidemic, 10.5% patients do not yet have 
final outcomes established, but our sample size of those 
who do have an established outcome is still greater than 
many other UK COVID-19 cohorts. While we recognise 
that the cohort was drawn from a region with high socio-
economic status, it is difficult to know the extent of this 
status in individual patients. However, Surrey represents 
the greatest proportion of high socioeconomic status resi-
dents compared with anywhere else in the UK. Although we 
show a high rate of admission to hospital for patients from 
different ethnic backgrounds there is no overall outcome 
difference, this result must be interpreted with caution as 
the number of patients from any ethnic group was limited.
CONCLUSIONS
We show that rates of complication and death due to 
COVID-19 are as high in a UK region in the top deciles 
of health and financial well- being as other populations 
described elsewhere. The findings underscore the potential 
universal reach of the disease regardless of socioeconomic 
background.
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